Literature DB >> 22843787

Outcomes of restrictive cardiomyopathy in childhood and the influence of phenotype: a report from the Pediatric Cardiomyopathy Registry.

Steven A Webber1, Steven E Lipshultz, Lynn A Sleeper, Minmin Lu, James D Wilkinson, Linda J Addonizio, Charles E Canter, Steven D Colan, Melanie D Everitt, John Lynn Jefferies, Paul F Kantor, Jacqueline M Lamour, Renee Margossian, Elfriede Pahl, Paolo G Rusconi, Jeffrey A Towbin.   

Abstract

BACKGROUND: Restrictive cardiomyopathy (RCM) has been associated with poor prognosis in childhood. The goal of the present analysis was to use the Pediatric Cardiomyopathy Registry to analyze outcomes of childhood RCM, with a focus on the impact of phenotype comparing pure RCM with cases that have additional features of hypertrophic cardiomyopathy (HCM). METHODS AND
RESULTS: We analyzed the Pediatric Cardiomyopathy Registry database (1990-2008; N=3375) for cases of RCM. Cases were defined as pure when RCM was the only assigned diagnosis. Additional documentation of HCM at any time was used as the criterion for RCM/HCM phenotype. RCM accounted for 4.5% of cases of cardiomyopathy. In 101 (66%), pure RCM was diagnosed; in 51 (34%), there was a mixed phenotype. Age at diagnosis was not different between groups, but 10% of the pure RCM group was diagnosed in infancy versus 24% of the RCM/HCM group. Freedom from death was comparable between groups with 1-, 2-, and 5-year survival of RCM 82%, 80%, and 68% versus RCM/HCM 77%, 74%, and 68%. Transplant-free survival was 48%, 34%, and 22% and 65%, 53%, and 43%, respectively (P=0.011). Independent risk factors at diagnosis for lower transplant-free survival were heart failure (hazard ratio 2.20, P=0.005), lower fractional shortening z score (hazard ratio 1.12 per 1 SD decrease in z score, P=0.014), and higher posterior wall thickness in the RCM/HCM group only (hazard ratio 1.32, P<0.001). Overall, outcomes were worse than for all other forms of cardiomyopathy.
CONCLUSIONS: Transplant-free survival is poor for RCM in childhood. Survival is independent of phenotype; however, the RCM/HCM phenotype has significantly better transplant-free survival. CLINICAL TRIALS REGISTRATION: URL: http://www.clinicaltrials.gov. Unique Identifier: NCT00005391.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22843787     DOI: 10.1161/CIRCULATIONAHA.112.104638

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  33 in total

Review 1.  Pediatric heart transplantation: long-term outcomes.

Authors:  Anne I Dipchand; Jessica A Laks
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2019-05-29

Review 2.  Pediatric Cardiomyopathies.

Authors:  Teresa M Lee; Daphne T Hsu; Paul Kantor; Jeffrey A Towbin; Stephanie M Ware; Steven D Colan; Wendy K Chung; John L Jefferies; Joseph W Rossano; Chesney D Castleberry; Linda J Addonizio; Ashwin K Lal; Jacqueline M Lamour; Erin M Miller; Philip T Thrush; Jason D Czachor; Hiedy Razoky; Ashley Hill; Steven E Lipshultz
Journal:  Circ Res       Date:  2017-09-15       Impact factor: 17.367

3.  Utility of Echocardiography in the Assessment of Left Ventricular Diastolic Function and Restrictive Physiology in Children and Young Adults with Restrictive Cardiomyopathy: A Comparative Echocardiography-Catheterization Study.

Authors:  Thomas D Ryan; Peace C Madueme; John L Jefferies; Erik C Michelfelder; Jeffrey A Towbin; Jessica G Woo; Rashmi D Sahay; Eileen C King; Roberta Brown; Ryan A Moore; Michelle A Grenier; Bryan H Goldstein
Journal:  Pediatr Cardiol       Date:  2016-11-23       Impact factor: 1.655

Review 4.  Cardiomyopathy With Restrictive Physiology in Sickle Cell Disease.

Authors:  Omar Niss; Charles T Quinn; Adam Lane; Joshua Daily; Philip R Khoury; Nihal Bakeer; Thomas R Kimball; Jeffrey A Towbin; Punam Malik; Michael D Taylor
Journal:  JACC Cardiovasc Imaging       Date:  2016-02-17

5.  Does Survival on the Heart Transplant Waiting List Depend on the Underlying Heart Disease?

Authors:  Eileen M Hsich; Joseph G Rogers; Dennis M McNamara; David O Taylor; Randall C Starling; Eugene H Blackstone; Jesse D Schold
Journal:  JACC Heart Fail       Date:  2016-05-11       Impact factor: 12.035

Review 6.  Pediatric heart transplantation-indications and outcomes in the current era.

Authors:  Philip T Thrush; Timothy M Hoffman
Journal:  J Thorac Dis       Date:  2014-08       Impact factor: 2.895

Review 7.  Importance of genetic evaluation and testing in pediatric cardiomyopathy.

Authors:  Muhammad Tariq; Stephanie M Ware
Journal:  World J Cardiol       Date:  2014-11-26

8.  Toward Personalized Medicine: Does Genetic Diagnosis of Pediatric Cardiomyopathy Influence Patient Management?

Authors:  Teresa M Lee; Stephanie M Ware
Journal:  Prog Pediatr Cardiol       Date:  2015-07-01

9.  Genetic background of Japanese patients with pediatric hypertrophic and restrictive cardiomyopathy.

Authors:  Takeharu Hayashi; Kousuke Tanimoto; Kayoko Hirayama-Yamada; Etsuko Tsuda; Mamoru Ayusawa; Shinichi Nunoda; Akira Hosaki; Akinori Kimura
Journal:  J Hum Genet       Date:  2018-06-15       Impact factor: 3.172

10.  Sickle cell anemia mice develop a unique cardiomyopathy with restrictive physiology.

Authors:  Nihal Bakeer; Jeanne James; Swarnava Roy; Janaka Wansapura; Shiva Kumar Shanmukhappa; John N Lorenz; Hanna Osinska; Kurt Backer; Anne-Cecile Huby; Archana Shrestha; Omar Niss; Robert Fleck; Charles T Quinn; Michael D Taylor; Enkhsaikhan Purevjav; Bruce J Aronow; Jeffrey A Towbin; Punam Malik
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.